Bruce Ricker
Family Medicine · Mount Ayr, IANPI 1851441760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$388
- Novo Nordisk$354
- AstraZeneca$302
- Amgen$300
- Boehringer Ingelheim$238
- Novartis$167
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,895100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $388 |
| Novo Nordisk | 16 | $354 |
| AstraZeneca | 18 | $302 |
| Amgen | 22 | $300 |
| Boehringer Ingelheim | 16 | $238 |
| Novartis | 10 | $167 |
| Mylan Specialty L.p. | 11 | $143 |
| Lilly USA, LLC | 8 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $120 |
| E.r. Squibb & Sons, L.L.C. | 8 | $110 |
| GSK | 5 | $67 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| AbbVie(2 entities) | 4 | $57 |
| Merck | 4 | $55 |
| Johnson & Johnson | 4 | $49 |
| Kowa Pharmaceuticals America, Inc. | 4 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Verona Pharma, Inc. | 2 | $28 |
| Astellas Pharma US Inc | 2 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Abiomed | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$125
How this compares
$2,895 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $64,431 |
| EliquisApixaban | 36 | $37,338 |
| JardianceEmpagliflozin | 26 | $26,976 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $22,215 |
| MyrbetriqMirabegron | 23 | $8,935 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,726 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,667 |
| Gabapentin | 95 | $1,482 |
| Levothyroxine Sodium | 147 | $1,370 |
| Tamsulosin Hcl | 65 | $1,179 |
| Ventolin HfaAlbuterol Sulfate | 35 | $1,124 |
| Potassium Chloride | 42 | $955 |
| Atorvastatin Calcium | 94 | $650 |
| Pantoprazole Sodium | 58 | $645 |
| Sertraline Hcl | 47 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $354 | $64,43155 claims |
| PfizerEliquis | $388 | $37,33836 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $67 | $33,60952 claims |
| Boehringer IngelheimJardiance | $238 | $26,97626 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $8,93523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Mount Ayr
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
- Laura MoellerAmes$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.